MBX Biosciences, Inc. announced its financial results for the year ended December 31, 2025, highlighting a pro forma cash position of $459.1 million. The company is on track to initiate a Phase 3 trial for canvuparatide in Q3 2026 following a successful FDA meeting.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.